Jeff Sharman, MD
Medical Oncology · Eugene, ORNPI 1659596179
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $237,290 of the $263,910 with a category attached, or 89.9%. It is spread thinly across 28 manufacturers, the largest accounting for just 21.5%. Reporting peaked in 2021 at $68,626 and has fallen 52.7% since, to $32,442 in 2025. Among medical oncology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $1221.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$57K
- Genentech, Inc.$25K
- AbbVie$25K
- E.r. Squibb & Sons, L.L.C.$18K
- Eli Lilly$16K
- Pfizer$15K
- plus $108K from 22 others
Across 2,345 payments — averaging $9122.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$8M
- Acerta Pharma LLC$3.1M
- Genentech, Inc.$2.9M
- Bristol Myers Squibb$1.6M
- Beone Medicines Ltd.$1.2M
- Astrazeneca UK Limited$897K
- plus $3.7M from 20 others
What the payments were for
- Consulting fees$237,29090%
- Speaking & faculty fees$16,9186%
- Travel & lodging$5,8822%
- Food & beverage$3,4821%
- Education$3380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $56,766 |
| Genentech, Inc. | 16 | $25,494 |
| AbbVie | 32 | $24,777 |
| E.r. Squibb & Sons, L.L.C. | 12 | $17,998 |
| Eli Lilly | 13 | $16,199 |
| Pfizer | 7 | $15,118 |
| Astrazeneca UK Limited | 12 | $14,126 |
| Beigene USA, Inc. | 11 | $13,515 |
| Bristol Myers Squibb | 8 | $12,445 |
| Janssen Global Services, LLC | 12 | $9,663 |
| TG Therapeutics, Inc. | 5 | $8,100 |
| F. Hoffmann-la Roche AG | 11 | $6,572 |
| Pharmacyclics LLC, An Abbvie Company | 9 | $6,226 |
| Merck | 2 | $5,490 |
| Beone Medicines USA, Inc. | 5 | $5,299 |
| Novartis | 2 | $4,943 |
| Lilly USA, LLC | 5 | $4,376 |
| Roche Products Limited | 1 | $3,280 |
| Beigene, Ltd. | 1 | $3,088 |
| Genentech USA, Inc. | 6 | $2,971 |
| Genmab U.S., Inc. | 4 | $2,469 |
| Bayer | 2 | $2,100 |
| ADC Therapeutics America, Inc. | 1 | $1,400 |
| Hoffmann-la Roche Limited | 3 | $951 |
| Secura Bio, Inc. | 1 | $500 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$263,910 in reported general payments places this provider in the 95th percentile of 92 medical oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 155 | $2,125,897 |
| CalquenceAcalabrutinib Maleate | 130 | $1,870,371 |
| Lenalidomide | 66 | $843,879 |
| RevlimidLenalidomide | 38 | $628,720 |
| ImbruvicaIbrutinib | 35 | $554,891 |
| PomalystPomalidomide | 20 | $433,317 |
| OjjaaraMomelotinib Dihydrochloride | 13 | $364,875 |
| CabometyxCabozantinib S-Malate | 13 | $338,241 |
| VenclextaVenetoclax | 21 | $311,965 |
| JakafiRuxolitinib Phosphate | 18 | $307,220 |
| VerzenioAbemaciclib | 20 | $306,018 |
| JaypircaPirtobrutinib | 14 | $297,141 |
| SprycelDasatinib | 16 | $159,575 |
| EliquisApixaban | 65 | $39,547 |
| GranixTbo-Filgrastim | 11 | $19,915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $13,515 | $2,125,897155 claims |
| AstraZenecaCalquence | $56,766 | $1,870,371130 claims |
| Bristol Myers SquibbRevlimid | $12,445 | $628,72038 claims |
| Lilly USA, LLCVerzenio, Jaypirca | $4,376 | $603,15834 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $17,998 | $592,89236 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $6,226 | $554,89135 claims |
| AbbVieVenclexta, Creon | $24,777 | $323,95433 claims |
| PfizerEliquis | $15,118 | $39,54765 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 medical oncology providers in Oregon.
Other medical oncology in Eugene
- Keith GoldsteinEugene$2K
- Benjamin ChoEugene$488
- David HufnagelEugene$329
- David PagePortland$238K
- Rachel SanbornPortland$233K
- Matthew TaylorPortland$231K
- Tomasz BeerPortland$102K
- Alison ConlinPortland$85K
- Shivaani KummarPortland$66K
- Stacy LewisPortland$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.